FY2021 EPS Estimates for Verrica Pharmaceuticals Inc. Boosted by Analyst (NASDAQ:VRCA)

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) – Equities research analysts at Jefferies Financial Group raised their FY2021 earnings per share (EPS) estimates for Verrica Pharmaceuticals in a research note issued to investors on Monday, January 10th. Jefferies Financial Group analyst D. Steinberg now expects that the company will post earnings of ($1.41) per share for the year, up from their previous forecast of ($1.54). Jefferies Financial Group currently has a “Buy” rating and a $20.00 price target on the stock. Jefferies Financial Group also issued estimates for Verrica Pharmaceuticals’ Q4 2021 earnings at ($0.46) EPS, FY2022 earnings at ($2.48) EPS, FY2023 earnings at ($1.59) EPS, FY2024 earnings at ($0.44) EPS and FY2025 earnings at $0.72 EPS.

VRCA has been the topic of several other reports. Needham & Company LLC lowered their target price on shares of Verrica Pharmaceuticals from $22.00 to $20.00 and set a “buy” rating on the stock in a research report on Tuesday, September 21st. HC Wainwright restated a “buy” rating and set a $19.00 target price on shares of Verrica Pharmaceuticals in a research report on Tuesday, November 30th. Royal Bank of Canada restated a “buy” rating and set a $16.00 target price on shares of Verrica Pharmaceuticals in a research report on Tuesday, November 23rd. Finally, Zacks Investment Research lowered shares of Verrica Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, October 13th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, Verrica Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $18.00.

Shares of Verrica Pharmaceuticals stock opened at $8.32 on Thursday. Verrica Pharmaceuticals has a 52-week low of $8.15 and a 52-week high of $18.42. The company’s 50-day simple moving average is $10.14 and its 200-day simple moving average is $11.06. The firm has a market cap of $228.96 million, a price-to-earnings ratio of -5.70 and a beta of 2.04.

Verrica Pharmaceuticals (NASDAQ:VRCA) last issued its quarterly earnings results on Friday, November 12th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.04.

In other news, Director Paul B. Manning acquired 30,023 shares of Verrica Pharmaceuticals stock in a transaction that occurred on Thursday, December 2nd. The shares were acquired at an average price of $9.45 per share, with a total value of $283,717.35. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 40.20% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the stock. BNP Paribas Arbitrage SA grew its holdings in Verrica Pharmaceuticals by 307.4% during the 3rd quarter. BNP Paribas Arbitrage SA now owns 2,579 shares of the company’s stock valued at $32,000 after purchasing an additional 1,946 shares in the last quarter. Meeder Asset Management Inc. acquired a new position in Verrica Pharmaceuticals during the 2nd quarter worth $47,000. Nisa Investment Advisors LLC acquired a new position in Verrica Pharmaceuticals during the 2nd quarter worth $51,000. Barclays PLC grew its holdings in Verrica Pharmaceuticals by 213.5% during the 3rd quarter. Barclays PLC now owns 5,352 shares of the company’s stock worth $67,000 after acquiring an additional 3,645 shares in the last quarter. Finally, HighVista Strategies LLC acquired a new position in Verrica Pharmaceuticals during the 3rd quarter worth $137,000. 33.33% of the stock is currently owned by institutional investors and hedge funds.

Verrica Pharmaceuticals Company Profile

Verrica Pharmaceuticals, Inc engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. Its lead product candidate VP-102, is a proprietary topical therapy used in common skin indications including molluscum contagiosum and verruca vulgaris. The company was founded by Matthew Davidson on July 3, 2013 and is headquartered in West Chester, PA.

Further Reading: Bear Market

Receive News & Ratings for Verrica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verrica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.